Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (ACRV)
CUSIP: 004890109
Q2 2023 13F Holders as of 30 Jun 2023
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Shares outstanding
- 38,870,454
- Total 13F shares
- 15,126,531
- Share change
- -89,651
- Total reported value
- $196,038,750
- Price per share
- $12.96
- Number of holders
- 40
- Value change
- -$1,147,208
- Number of buys
- 22
- Number of sells
- 15
Quarterly Holders Quick Answers
What is CUSIP 004890109?
CUSIP 004890109 identifies ACRV - Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 004890109:
Top shareholders of ACRV - Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. |
13F
|
Company |
12%
|
4,810,508
|
$61,045,347 | — | 31 Mar 2023 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
7.7%
|
3,007,858
|
$38,169,718 | — | 31 Mar 2023 | |
| Sands Capital Alternatives, LLC |
13F
|
Company |
4.3%
|
1,652,605
|
$20,971,557 | — | 31 Mar 2023 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
4.2%
|
1,641,022
|
$20,148,346 | — | 31 Mar 2023 | |
| Chione Ltd |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
3,848,632
|
$16,741,549 | — | 26 Jun 2023 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
2.3%
|
888,130
|
$11,137,595 | — | 31 Mar 2023 | |
| FEDERATED HERMES, INC. |
13F
|
Company |
1.6%
|
613,625
|
$7,786,901 | — | 31 Mar 2023 | |
| MARSHALL WACE, LLP |
13F
|
Company |
1.5%
|
597,469
|
$7,581,882 | — | 31 Mar 2023 | |
| BlackRock Finance, Inc. |
13F
|
Company |
1.2%
|
474,227
|
$6,017,940 | — | 31 Mar 2023 | |
| VANGUARD GROUP INC |
13F
|
Company |
1.1%
|
409,215
|
$5,192,938 | — | 31 Mar 2023 | |
| NEA Management Company, LLC |
13F
|
Company |
1.2%
|
481,677
|
$4,889,985 | — | 31 Mar 2023 | |
| Wellington Biomedical Innovation Master Investors (Cayman) I L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
888,130
|
$3,863,366 | — | 17 Nov 2022 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.45%
|
175,404
|
$2,225,876 | — | 31 Mar 2023 | |
| STATE STREET CORP |
13F
|
Company |
0.22%
|
85,339
|
$1,082,952 | — | 31 Mar 2023 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.18%
|
69,751
|
$885,140 | — | 31 Mar 2023 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
0.16%
|
61,896
|
$785,460 | — | 31 Mar 2023 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.15%
|
58,209
|
$738,672 | — | 31 Mar 2023 | |
| DAFNA Capital Management LLC |
13F
|
Company |
0.13%
|
51,148
|
$649,068 | — | 31 Mar 2023 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.08%
|
32,262
|
$409,405 | — | 31 Mar 2023 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.06%
|
22,837
|
$289,801 | — | 31 Mar 2023 | |
| BARCLAYS PLC |
13F
|
Company |
0.04%
|
16,983
|
$215,514 | — | 31 Mar 2023 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.04%
|
13,718
|
$174,081 | — | 31 Mar 2023 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.02%
|
6,630
|
$84,000 | — | 31 Mar 2023 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.02%
|
5,856
|
$74,313 | — | 31 Mar 2023 | |
| MORGAN STANLEY |
13F
|
Company |
0.01%
|
5,624
|
$71,368 | — | 31 Mar 2023 | |
| UBS Group AG |
13F
|
Company |
0.01%
|
5,396
|
$68,475 | — | 31 Mar 2023 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.01%
|
5,369
|
$68,133 | — | 31 Mar 2023 | |
| MetLife Investment Management, LLC |
13F
|
Company |
0.01%
|
5,081
|
$64,477 | — | 31 Mar 2023 | |
| AMERICAN INTERNATIONAL GROUP, INC. |
13F
|
Company |
0.01%
|
4,178
|
$53,019 | — | 31 Mar 2023 | |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM |
13F
|
Company |
0.01%
|
3,218
|
$40,836 | — | 31 Mar 2023 | |
| NEW YORK STATE COMMON RETIREMENT FUND |
13F
|
Company |
0.01%
|
2,206
|
$27,994 | — | 31 Mar 2023 | |
| STRS OHIO |
13F
|
Company |
0%
|
1,800
|
$22,000 | — | 31 Mar 2023 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0%
|
1,588
|
$20,152 | — | 31 Mar 2023 | |
| AMALGAMATED BANK |
13F
|
Company |
0%
|
1,130
|
$14,000 | — | 31 Mar 2023 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0%
|
1,092
|
$14,000 | — | 31 Mar 2023 | |
| Legal & General Group Plc |
13F
|
Company |
0%
|
924
|
$11,726 | — | 31 Mar 2023 | |
| Ameritas Investment Partners, Inc. |
13F
|
Company |
0%
|
695
|
$8,820 | — | 31 Mar 2023 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0%
|
665
|
$8,000 | — | 31 Mar 2023 | |
| METROPOLITAN LIFE INSURANCE CO/NY |
13F
|
Company |
0%
|
523
|
$6,637 | — | 31 Mar 2023 | |
| CITIGROUP INC |
13F
|
Company |
0%
|
202
|
$2,563 | — | 31 Mar 2023 | |
| FMR LLC |
13F
|
Company |
0%
|
122
|
$1,548 | — | 31 Mar 2023 |
Institutional Holders of Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (ACRV) as of Q2 2023
As of 30 Jun 2023,
Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (ACRV) was held by
40 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
15,126,531 shares.
The largest 10 holders included
RA CAPITAL MANAGEMENT, L.P., PERCEPTIVE ADVISORS LLC, Sands Capital Ventures, LLC, CITADEL ADVISORS LLC, WELLINGTON MANAGEMENT GROUP LLP, MARSHALL WACE, LLP, BlackRock Inc., NEA Management Company, LLC, VANGUARD GROUP INC, and FEDERATED HERMES, INC..
This page lists
40
institutional shareholders reporting positions in this security
for the Q2 2023 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2023 vs Q1 2023 Across Filers
Q1 2023 holders
39
Q2 2023 holders
40
Holder diff
1
| Investor | Q1 2023 Shares | Q2 2023 Shares | Share Diff | Share Chg % | Q1 2023 Value $ | Q2 2023 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.